MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALMKS • ES0105463006

8.65 EUR
+0.05 (+0.58%)
Last: Feb 3, 2026, 07:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALMKS. ALMKS was compared to 68 industry peers in the Media industry. ALMKS has a bad profitability rating. Also its financial health evaluation is rather negative. ALMKS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ALMKS has reported negative net income.
  • In the past year ALMKS had a positive cash flow from operations.
  • ALMKS had negative earnings in 4 of the past 5 years.
  • Of the past 5 years ALMKS 4 years had a positive operating cash flow.
ALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -0.99%, ALMKS is doing worse than 67.65% of the companies in the same industry.
  • ALMKS has a worse Return On Equity (-6.62%) than 67.65% of its industry peers.
  • With a decent Return On Invested Capital value of 7.51%, ALMKS is doing good in the industry, outperforming 69.12% of the companies in the same industry.
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROIC 7.51%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALMKS.PA Yearly ROA, ROE, ROICALMKS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

  • Looking at the Operating Margin, with a value of 1.86%, ALMKS is in line with its industry, outperforming 41.18% of the companies in the same industry.
  • ALMKS's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 20.80%, ALMKS is doing worse than 80.88% of the companies in the same industry.
  • ALMKS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.86%
PM (TTM) N/A
GM 20.8%
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
ALMKS.PA Yearly Profit, Operating, Gross MarginsALMKS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

2

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ALMKS is creating some value.
  • Compared to 1 year ago, ALMKS has more shares outstanding
  • ALMKS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALMKS has been reduced compared to a year ago.
ALMKS.PA Yearly Shares OutstandingALMKS.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALMKS.PA Yearly Total Debt VS Total AssetsALMKS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 1.74, we must say that ALMKS is in the distress zone and has some risk of bankruptcy.
  • ALMKS has a better Altman-Z score (1.74) than 60.29% of its industry peers.
  • ALMKS has a debt to FCF ratio of 1140.00. This is a negative value and a sign of low solvency as ALMKS would need 1140.00 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1140.00, ALMKS is doing worse than 60.29% of the companies in the same industry.
  • A Debt/Equity ratio of 0.46 indicates that ALMKS is not too dependend on debt financing.
  • ALMKS has a Debt to Equity ratio of 0.46. This is in the better half of the industry: ALMKS outperforms 61.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Altman-Z 1.74
ROIC/WACC1.1
WACC6.86%
ALMKS.PA Yearly LT Debt VS Equity VS FCFALMKS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that ALMKS may have some problems paying its short term obligations.
  • ALMKS has a worse Current ratio (0.76) than 70.59% of its industry peers.
  • ALMKS has a Quick Ratio of 0.76. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.73, ALMKS is doing worse than 64.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.73
ALMKS.PA Yearly Current Assets VS Current LiabilitesALMKS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 61.58% over the past year.
  • The Revenue has grown by 16.22% in the past year. This is quite good.
  • Measured over the past years, ALMKS shows a very strong growth in Revenue. The Revenue has been growing by 51.26% on average per year.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%

3.2 Future

  • Based on estimates for the next years, ALMKS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.62% on average per year.
  • Based on estimates for the next years, ALMKS will show a very strong growth in Revenue. The Revenue will grow by 22.10% on average per year.
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALMKS.PA Yearly Revenue VS EstimatesALMKS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ALMKS.PA Yearly EPS VS EstimatesALMKS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • ALMKS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALMKS is valuated quite expensively with a Price/Forward Earnings ratio of 35.33.
  • 64.71% of the companies in the same industry are cheaper than ALMKS, based on the Price/Forward Earnings ratio.
  • ALMKS's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.51.
Industry RankSector Rank
PE N/A
Fwd PE 35.33
ALMKS.PA Price Earnings VS Forward Price EarningsALMKS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALMKS indicates a slightly more expensive valuation: ALMKS is more expensive than 61.76% of the companies listed in the same industry.
  • ALMKS's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ALMKS is more expensive than 60.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1553.54
EV/EBITDA 9.4
ALMKS.PA Per share dataALMKS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALMKS's earnings are expected to grow with 15.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y15.62%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ALMKS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAKING SCIENCE GROUP SA

EPA:ALMKS (2/3/2026, 7:00:00 PM)

8.65

+0.05 (+0.58%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)07-31
Earnings (Next)N/A
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners61.03%
Ins Owner ChangeN/A
Market Cap77.68M
Revenue(TTM)274.00M
Net Income(TTM)-1.72M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 35.33
P/S 0.28
P/FCF 1553.54
P/OCF 235.39
P/B 2.99
P/tB N/A
EV/EBITDA 9.4
EPS(TTM)-0.2
EYN/A
EPS(NY)0.24
Fwd EY2.83%
FCF(TTM)0.01
FCFY0.06%
OCF(TTM)0.04
OCFY0.42%
SpS30.51
BVpS2.9
TBVpS-4.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROCE 10.22%
ROIC 7.51%
ROICexc 13.46%
ROICexgc N/A
OM 1.86%
PM (TTM) N/A
GM 20.8%
FCFM 0.02%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
F-Score6
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Debt/EBITDA 1.03
Cap/Depr 4.29%
Cap/Sales 0.1%
Interest Coverage 1.14
Cash Conversion 2.84%
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.73
Altman-Z 1.74
F-Score6
WACC6.86%
ROIC/WACC1.1
Cap/Depr(3y)13.72%
Cap/Depr(5y)311.76%
Cap/Sales(3y)0.4%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A
EBIT growth 1Y278.77%
EBIT growth 3YN/A
EBIT growth 5Y41.58%
EBIT Next Year200%
EBIT Next 3Y56.86%
EBIT Next 5YN/A
FCF growth 1Y103.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y178.57%
OCF growth 3Y-64.23%
OCF growth 5YN/A

MAKING SCIENCE GROUP SA / ALMKS.PA FAQ

What is the fundamental rating for ALMKS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALMKS.PA.


Can you provide the valuation status for MAKING SCIENCE GROUP SA?

ChartMill assigns a valuation rating of 0 / 10 to MAKING SCIENCE GROUP SA (ALMKS.PA). This can be considered as Overvalued.


What is the profitability of ALMKS stock?

MAKING SCIENCE GROUP SA (ALMKS.PA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MAKING SCIENCE GROUP SA?

The Earnings per Share (EPS) of MAKING SCIENCE GROUP SA (ALMKS.PA) is expected to decline by -27.27% in the next year.